Levation Pharma
Jerusalem, Israel· Est.
A topical, drug‑delivered solution for age‑related eyelid droop, aiming to replace blepharoplasty.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A topical, drug‑delivered solution for age‑related eyelid droop, aiming to replace blepharoplasty.
Ophthalmology
Technology Platform
Proprietary aqueous gel delivering oxymetazoline to Mueller’s muscle for topical lid elevation.
Opportunities
Large unmet need for non‑surgical ptosis treatment and potential to capture market share from blepharoplasty.
Risk Factors
Clinical efficacy uncertainty, regulatory approval challenges, and competition from other topical or device therapies.
Competitive Landscape
Main competition is surgical blepharoplasty; LEV‑102 differentiates by offering a minimally invasive, daily‑use topical solution.